04 Oct, EOD - Indian

SENSEX 81688.45 (-0.98)

Nifty 50 25014.6 (-0.93)

Nifty Bank 51462.05 (-0.74)

Nifty IT 41912.5 (0.36)

Nifty Midcap 100 58474.45 (-0.93)

Nifty Next 50 74620.25 (-1.10)

Nifty Pharma 23094.7 (-0.36)

Nifty Smallcap 100 18758.65 (-1.02)

04 Oct, EOD - Global

NIKKEI 225 38635.62 (0.22)

HANG SENG 22736.87 (2.82)

S&P 5807.5 (0.80)

Login/Signup
LOGIN HERE
Cancel

Bafna Pharmaceuticals Ltd

You are Here : Home > Markets > CompanyInformation > Board Meeting
BSE Code : 532989 | NSE Symbol : BAFNAPH | ISIN : INE878I01022 | Industry : Pharmaceuticals |


Board Meeting
Announcement Date Date Of Meeting Purpose Detail
06-Aug-2024 13-Aug-2024 Quarterly Results BAFNA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2024 inter alia to consider and approve the Unaudited Financial Results for the First Quarter ended June 30 2024.
22-May-2024 29-May-2024 Accounts BAFNA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2024 inter alia to consider and approve Consideration and Approval of the Audited Financial Results of the Company for the Quarter and Year ended March 31 2024. We are herewith submitting the Audited Financial Results for the Quarter & Year ended 31/03/2024 The Board of Directors in the meeting held on 29/05/2019 has inter-alia (i) approved the audited financial results of the Company for the quarter & year ended March 31, 2024; (ii) ii). .... Read More.. (As Per BSE Announcement Dated on 29.05.2024)
02-Feb-2024 12-Feb-2024 Quarterly Results BAFNA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2024 inter alia to consider and approve A meeting of board of directors of the Company is scheduled to be held on Monday February 12 2024 inter-alia to consider and approve the Un-Audited Standalone Financial Results of the Company for the third quarter of FY24 ended December 31 2023 together with the Limited Review Report for the said period. we wish to inform that at the meeting of the Board of Directors of the Company held today i.e., February 12, 2024, Monday, the results of the quarter ended on December 31, 2023, duly reviewed by Audit Committee, inter-alia has been considered and approved by the Board of Directors of the Company. (As Per BSE Announcement dated on 12.02.2024)
30-Oct-2023 09-Nov-2023 Quarterly Results BAFNA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2023 inter alia to consider and approve A meeting of Board of Directors of the Company is scheduled to be held on Thursday November 09 2023 inter-alia to consider and approve the Un-Audited Standalone Financial Results of the Company for the second quarter of FY24 and half year ended September 30 2023 together with the Limited Review Report for the said period. We wish to inform that at the meeting of the Board of Directors of the Company held today i.e., November 09, 2023, Thursday, the results for the quarter and half-year ended on September 30, 2023, duly reviewed and recommended by the Audit Committee, inter-alia, has been considered and approved by the Board of Directors of the Company. In this regard, we enclose the following: (As per BSE Announcement Dated on 09/11/2023) we wish to inform that at the meeting of the Board of Directors of the Company held on November 09, 2023, the results for the quarter ended September 30, 2023, duly reviewed and recommended by the Audit Committee, inter-alia, has been considered and approved by the Board of Directors of the Company. (As Per BSE Announcement Dated on 10.11.2023) As per BSE e-mail dated December 08, 2023, certified true copy of the resolution passed in the Board of Directors in their meeting held on November 09, 2023, along with the signed financials submitted on the date of Board meeting. (As Per BSE Announcement Dated on 09.12.2023)
03-Aug-2023 11-Aug-2023 Quarterly Results BAFNA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2023 inter alia to consider and approve the Un-Audited Standalone Financial Results of the Company for the first quarter of FY24 ended June 30 2023 together with the Limited Review Report for the said period. We wish to inform that at the meeting of the Board of Directors of the Company held today i.e., August 11, 2023, Friday, the results for the quarter ended on June 30, 2023, duly reviewed and recommended by the Audit Committee, inter-alia, has been considered and approved by the Board of Directors of the Company. The Board noted the issue of non-compliance with the Regulation 23(9) of SEBI (LODR) Regulations, 2015 (As Per BSE Announcement Dated on 11.08.2023)
23-Jun-2023 26-Jun-2023 Change in Directors BAFNA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/06/2023 inter alia to consider and approve inter alia to consider and approve the appointment of 1. Mr. Vinayak Dinesh Dendukuri (DIN: 07601309) as Additional Director designated as Whole-time Director - Operation. 2. Mr. Upendar Mekala Reddy (DIN: 08898174) as Additional Director designated as Non-Executive Non-independent Director; 3. Mr. Krishna Yeachuri (DIN: 00066898) as Additional Director designated as Non-Executive Independent Director and any other business with the permission of the Chair. Based on the recommendations of the Nomination and Remuneration Committee of Board of Directors, have interalia discussed and approved the appointment of following directors: 1. Mr. Vinayak Dinesh Dendukuri (DIN: 07601309) as Additional Director designated as Whole-time Director - Operation. 2. Mr. Upendar Mekala Reddy (DIN: 08898174) as Additional Director designated as Non-Executive Non-independent Director; 3. Mr. Krishna Yeachuri (DIN: 00066898) as Additional Director designated as Non-Executive Independent Director. (As Per BSE Announcement Dated on 27/06/2023)
17-May-2023 27-May-2023 Accounts BAFNA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/05/2023 inter alia to consider and approve the Audited Financial Results of the Company for the quarter and financial year ended 31 March 2023. The Board Meeting to be held on 24/05/2023 has been revised to 27/05/2023 The Board Meeting to be held on 24/05/2023 has been rescheduled to 27/05/2023 (As Per BSE Announcement Dated on 22.05.2023) We hereby inform you that the Board at its meeting held on May 27, 2023 had considered and approved the Audited Financial results for the quarter and year ended March 31, 2023. We herewith submit the Audited Financial results (standalone) for the quarter and year ended March 31, 2023, which was approved by the Board Of Directors in the Meeting held on 27.05.2023 (As Per BSE Announcement Dated on 27.05.2023)
04-Apr-2023 07-Apr-2023 Change in Other Executives BAFNA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/04/2023 inter alia to consider and approve To consider the appointment of Company Secretary cum Compliance Officer and any other business with the permission of the Chair Appointment of CS Vishnu Vasudeva Kuppa as Company Secretary and Compliance Officer of the Company w.e.f 07.04.2023. (As per BSE Announcement Dated on 07/04/2023)
01-Feb-2023 08-Feb-2023 Quarterly Results BAFNA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/02/2023 inter alia to consider and approve the Unaudited Results for the Nine Months Period and Quarter ended 31.12.2022 Unaudited financial results for the quarter and nine months ended 31.12.2022 along with limited review report (As per BSE Announcement Dated on 08/02/2023)
02-Nov-2022 11-Nov-2022 Quarterly Results BAFNA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2022 inter alia to consider and approve Board Meeting Intimation to consider the Unaudited Results for the Half year and Quarter ended 30.09.2022 Outcome of the Meeting of Board of Directors held on 11.11.2022 (As Per BSE Announcement dated on 11.11.2022)
04-Aug-2022 11-Aug-2022 Quarterly Results BAFNA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2022 inter alia to consider and approve The unaudited results for the quarter ended 30.06.2022 We would like to inform you that the Board at its meeting held today approved the unaudited financial results for the quarter ended 30th June 2022. Please find attached the unaudited financial results for the quarter ended 30th June 2022 along with the limited review report obtained from the statutory auditor of the Company. The Audit Committee of the Company has been reconstituted to include Ms. Chitra Ravichandran, Independent Director as member of the Committee. Site optimized for IE9 & above. : Disclaimer : Website Policies : Privacy Policy : Sitemap Copyright c BSE Ltd. All Rights Reserved. (As Per BSE Announcement Dated 11.08.2022)
20-May-2022 26-May-2022 Accounts BAFNA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/05/2022 inter alia to consider and approve We would like to inform that meeting of the Board of Directors of the Company will be held on Thursday 26th May 2022 to inter alia consider and adopt audited financial results for the quarter / year ended 31st March 2022 and any other business with the permission of the Chair. Further in accordance with the Code of Conduct for prevention of Insider Trading pursuant to the SEBI (Prohibition of Insider Trading) Regulations 2015 the trading window for dealing in securities of the Company has already been closed from 1st April 2022 and shall remain closed until 48 hours after the financial results approved at the meeting are made public. 1. AUDITED FINANCIAL RESULTS Approval of audited financial results of the Company for the quarter and year ended 31st March 2022. Please find enclosed the following: 1. Audited financial statements (standalone) for the quarter and year ended 31st March 2022 along with Auditor's report for the said period 2. Declaration on Unmodified Opinion in the Auditors' Report for Financial Year ended March 31, 2022 2. ANNUAL GENERAL MEETING The 27th Annual General Meeting of the members of the Company is scheduled to be held on Thursday, 28th July 2022 at 12:00 Noon through video conferencing and other audio visual means. 3. To open wholly owned subsidiary of Bafna Pharmaceuticals Limited in Australia. Bafna Pharmaceuticals Ltd has informed BSE regarding Outcome of Board Meeting held on May 26, 2022. (As Per BSE Announcement dated on 26.05.2022)
17-Mar-2022 21-Mar-2022 Change in Other Executives BAFNA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/03/2022 inter alia to consider and approve Notice is hereby given that a meeting of the Board of Directors of the Company will be held on Monday 21st day of March 2022 online through zoom video conferencing at 11.00 A.M to inter alia consider resignation and appointment of Company Secretary (KMP) of the Company and any other business with the permission of chair. Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Part A of Schedule III of said Regulations, this is to inform you that the Board of Directors in its meeting held today i.e. 21st March 2022 , considered and approved the appointment of Mrs. Roopa Ravikumar (Membership No: F11282) as Company Secretary & Compliance officer of the Company w.e.f 22nd March 2022. Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Part A of Schedule III of said Regulations, this is to inform you that the Board of Directors in its meeting held today i.e. 21st March 2022 , considered and approved the following: 1. Resignation by Mr. Jitendra Kumar Pal from the post of Company Secretary & Compliance officer of the Company due to personal reasons with effect from closure of business hours on 21st March 2022. 2.. Appointment of Mrs. Roopa Ravikumar (Membership No: F11282) as Company Secretary & Compliance officer of the Company w.e.f 22nd March 2022 (As Per BSE Announcement dated on 21.03.2022)
01-Feb-2022 10-Feb-2022 Quarterly Results BAFNA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2022 inter alia to consider and approve Notice is hereby given that a meeting of the Board of Directors of the Company will be held on Thursday 10th February 2022 to inter alia consider and adopt un-audited financial results for the quarter and nine months ended 31st December 2021 and any other business with the permission of the Chair. outcome of board meeting (As Per BSE Announcement Dated on 10/02/2022)
03-Nov-2021 12-Nov-2021 Quarterly Results Quarterly Results Bafna Pharmaceuticals Ltd has informed BSE regarding Outcome of Board Meeting held on November 12 2021. Pursuant to the Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, ('Listing Regulations') as amended, this is to inform you that the Board of Directors ('Board') of the Company, had at its meeting held today i.e. Friday, November 12, 2021, the Board has decided the following matters: 1. Approved the un - audited financial results of the Company for the quarter /half year ended September 30, 2021. Please find attached Limited Review Report from the Statutory Auditor. 2. Statutory Auditors comments along with Management's Reply: 3. Raising of funds by way of offer and issue of equity shares to the existing shareholders of the Company on a rights basis (Rights Issue) for an aggregate amount upto INR 50 Crore. 3. Raising of funds by way of offer and issue of equity shares to the existing shareholders of the Company on a rights basis (Rights Issue) for an aggregate amount upto INR 50 Crore. The Board has constituted a Rights Issue Committee of Directors for the above purpose and has authorised the Committee to determine the terms of the Rights Issue including the quantum of issue, rights entitlement ratio, issue price, issue size, book closure or record date, entitlement timing of the issue, appointment of intermediaries, etc., in consultation with the Lead Manager to the Right Issue and to decide all other matters relating to the Right Issue. Such details shall be informed and/or announced in due course as and when decided or required, as per applicable statutory provisions and depending upon the market conditions. The above proposal to issue of shares shall be subject to necessary approvals, confirmations and consents as may be necessary and in compliance with applicable law including Bafna Pharmaceuticals Ltd has informed BSE regarding Outcome of Board Meeting held on November 12, 2021. (As Per BSE Announcement Dated on 11/12/2021 9:02:22 AM)
1 2